Cargando…

Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent

The antitumour action of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) is mediated through tumour-selective antivascular effects and cytokine induction. This clinical phase I trial was conducted to examine its toxicity, maximum tolerated dose, pharmacokinetics (PK) and pharmacodynamics (PD). A second...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jameson, M B, Thompson, P I, Baguley, B C, Evans, B D, Harvey, V J, Porter, D J, McCrystal, M R, Small, M, Bellenger, K, Gumbrell, L, Halbert, G W, Kestell, P
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2003
Materias:	Clinical
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2741109/ https://www.ncbi.nlm.nih.gov/pubmed/12799625 http://dx.doi.org/10.1038/sj.bjc.6600992

Ejemplares similares

5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study
por: Rustin, G J S, et al.
Publicado: (2003)

The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice
por: Zhao, L, et al.
Publicado: (2002)

Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs.
por: Lash, C. J., et al.
Publicado: (1998)

Induction of endothelial cell apoptosis by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid
por: Ching, L-M, et al.
Publicado: (2002)

Identification of human-selective analogues of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)
por: Tijono, S M, et al.
Publicado: (2013)

Antitumour responses to flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid in immune deficient mice.
por: Ching, L. M., et al.
Publicado: (1992)

Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice
por: Ching, L-M, et al.
Publicado: (2004)

Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid.
por: Ching, L. M., et al.
Publicado: (1995)

Preclinical in vitro and in vivo activity of 5,6-dimethylxanthenone-4-acetic acid.
por: Laws, A. L., et al.
Publicado: (1995)

Thalidomide increases both intra-tumoural tumour necrosis factor-α production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid
por: Cao, Z, et al.
Publicado: (1999)

Production of tumour necrosis factor-alpha by cultured human peripheral blood leucocytes in response to the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (NSC 640488).
por: Philpott, M., et al.
Publicado: (1997)

Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity.
por: Ching, L. M., et al.
Publicado: (1998)

Proteomic response to 5,6-dimethylxanthenone 4-acetic acid (DMXAA, vadimezan) in human non-small cell lung cancer A549 cells determined by the stable-isotope labeling by amino acids in cell culture (SILAC) approach
por: Pan, Shu-Ting, et al.
Publicado: (2015)

Persistent induction of nitric oxide synthase in tumours from mice treated with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid.
por: Moilanen, E., et al.
Publicado: (1998)

Necrosis in non-tumour tissues caused by flavone acetic acid and 5,6-dimethyl xanthenone acetic acid.
por: Zwi, L. J., et al.
Publicado: (1990)

Combination therapy of simvastatin and 5, 6-dimethylxanthenone-4-acetic acid synergistically suppresses the aggressiveness of B16.F10 melanoma cells
por: Rauca, Valentin-Florian, et al.
Publicado: (2018)

Microbubble-enhanced ultrasound for the antivascular treatment and monitoring of hepatocellular carcinoma
por: D'Souza, Julia C., et al.
Publicado: (2019)

Antivascular Therapy for Epithelial Ovarian Cancer
por: Duhoux, Francois P., et al.
Publicado: (2010)

Dissection of stromal and cancer cell-derived signals in melanoma xenografts before and after treatment with DMXAA
por: Henare, K, et al.
Publicado: (2012)

Discovery of Novel STING Inhibitors Based on the Structure of the Mouse STING Agonist DMXAA
por: Chang, Jiajia, et al.
Publicado: (2023)

Remodeling tumor microenvironment by liposomal codelivery of DMXAA and simvastatin inhibits malignant melanoma progression
por: Rauca, Valentin-Florian, et al.
Publicado: (2021)

The STING agonist DMXAA triggers a cooperation between T lymphocytes and myeloid cells that leads to tumor regression
por: Weiss, Julia M., et al.
Publicado: (2017)

The chemotherapeutic agent DMXAA potently and specifically activates the TBK1–IRF-3 signaling axis
por: Roberts, Zachary J., et al.
Publicado: (2007)

Vascular disrupting agent DMXAA enhances the antitumor effects generated by therapeutic HPV DNA vaccines
por: Peng, Shiwen, et al.
Publicado: (2011)

The Chemotherapeutic Agent DMXAA as a Unique IRF3-Dependent Type-2 Vaccine Adjuvant
por: Tang, Choon Kit, et al.
Publicado: (2013)

HDAC4 Inhibitors as Antivascular Senescence Therapeutics
por: Huang, Chuoji, et al.
Publicado: (2022)

Binding-Pocket and Lid-Region Substitutions Render Human STING Sensitive to the Species-Specific Drug DMXAA
por: Gao, Pu, et al.
Publicado: (2014)

The Proper Administration Sequence of Radiotherapy and Anti-Vascular Agent—DMXAA Is Essential to Inhibit the Growth of Melanoma Tumors
por: Drzyzga, Alina, et al.
Publicado: (2021)

Visualizing the antivascular effect of bortezomib on the hypoxic tumor microenvironment
por: Sun, Xiaorong, et al.
Publicado: (2015)

Commentary: Antivascular endothelial growth factor and retinopathy of prematurity
por: Dudani, Ajay Indur, et al.
Publicado: (2019)

Nanomaterial-Based Antivascular Therapy in the Multimodal Treatment of Cancer
por: Ma, Xiaocong, et al.
Publicado: (2023)

Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11
por: Wildiers, H, et al.
Publicado: (2003)

Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging
por: Robinson, S P, et al.
Publicado: (2003)

Combination of anti-vascular agent - DMXAA and HIF-1α inhibitor - digoxin inhibits the growth of melanoma tumors
por: Smolarczyk, Ryszard, et al.
Publicado: (2018)

Use of antivascular endothelial growth factor for diabetic macular edema
por: Karim, Rushmia, et al.
Publicado: (2010)

Antivascular and antitumor properties of the tubulin-binding chalcone TUB091
por: Canela, María-Dolores, et al.
Publicado: (2016)

Intravital imaging and cavitation monitoring of antivascular ultrasound in tumor microvasculature
por: Zhao, Xiaoxiao, et al.
Publicado: (2023)

Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126
por: Bozec, A, et al.
Publicado: (2006)

The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations
por: Leach, M O, et al.
Publicado: (2005)

Author Correction: Combination of anti-vascular agent - DMXAA and HIF-1α inhibitor - digoxin inhibits the growth of melanoma tumors
por: Smolarczyk, Ryszard, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7gf7ljnh148oogccb1qi24rd4t